FibroBiologics to Present at the BIO International Convention 2025
HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present a company update at the BIO International Convention 2025, June 16-19, 2025, in Boston, MA. The presentation will include recent corporate milestones and research advances using fibroblast-based technology for indications such as wound healing, multiple sclerosis, and psoriasis.
“The BIO International Convention provides an ideal platform to showcase how FibroBiologics is potentially transforming the treatment landscape for chronic diseases,” said Pete O’Heeron. “With our Phase 1/2 clinical trial in diabetic foot ulcers wound healing set to begin later this year, we are demonstrating that fibroblast-based therapies have the potential to address the underlying biological dysfunction rather than managing symptoms. This could represent a fundamental shift in how we approach the treatment of chronic diseases.”
Details of the presentation are as follows:
Date: Tuesday, June 17, 2025
Time:10:45 a.m. ET
Location:Boston Convention & Exhibition Center, Room 154
To learn more about the event, please visit https://convention.bio.org/ or to schedule one-on-one meetings, please email FibroBiologicsIR@russopr.com.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains "forward-looking statements " as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning plans for, and the timing of, clinical trials. These forward-looking statements are based on FibroBiologics ' management 's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics ' management 's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors " and elsewhere in FibroBiologics ' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC 's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics ' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
© 2025 GlobeNewswire, Inc. All Rights Reserved.
